The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients.
C-Terminal cross-linked telopeptide of type I collagen
Cardiomyopathy
Friedreich ataxia
Serum biomarker
TT3
Journal
Cerebellum (London, England)
ISSN: 1473-4230
Titre abrégé: Cerebellum
Pays: United States
ID NLM: 101089443
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
30
08
2022
medline:
8
9
2023
pubmed:
7
9
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
Friedreich's ataxia (FRDA) is the most common inherited recessive ataxia. Cardiomyopathy (CM) with myocardial hypertrophy is the predominant cause of death. The presence of CM is variable and the risk factors for cardiac involvement are not entirely clear. Markers of collagen degradation, such as C-terminal cross-linked telopeptide of type I collagen (CTX-I), seem to be associated with unfavorable cardiovascular outcomes. The aim of our study was to measure serum CTX-I as a marker of cardiac fibrosis in FRDA patients. We measured serum CTX value in twenty-five FRDA patients (mean age, 31.3 ± 14.7 years) and nineteen healthy controls (mean age, 34.0 ± 13.5 years). Patients underwent echocardiography and SARA scale evaluation. CTX values were significantly higher in the patients than in the control group (31.82 ± 2.27 vs 16.44 ± 1.6 μg/L; p = 0.006). CTX-I was inversely correlated with age (R = - 0,535; n = 44; p < 0.001). The regression model identified disease duration and TT3 levels to be independent predictors of CTX-I (model R
Identifiants
pubmed: 36066808
doi: 10.1007/s12311-022-01475-4
pii: 10.1007/s12311-022-01475-4
doi:
Substances chimiques
Collagen Type I
0
Collagen
9007-34-5
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1034-1038Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Stehling O, Elsasser HP, Bruckel B, Muhlenhoff U, Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet. 2004;13:3007–15.
doi: 10.1093/hmg/ddh324
pubmed: 15509595
Sacca F, Puorro G, Antenora A, et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One. 2011;6:e17627.
doi: 10.1371/journal.pone.0017627
pubmed: 21412413
pmcid: 3055871
Payne RM, Peverill RE. Cardiomyopathy of Friedreich’s ataxia (FRDA). Ir J Med Sci. 2012;181:569–70.
doi: 10.1007/s11845-012-0808-7
pubmed: 22373590
Bourke T, Keane D. Friedreich’s Ataxia: a review from a cardiology perspective. Ir J Med Sci. 2011;180:799–805.
doi: 10.1007/s11845-011-0744-y
pubmed: 21822977
Coskun KO, Popov AF, Schmitto JD, et al. Feasibility of implantable cardioverter defibrillator treatment in five patients with familial Friedreich’s ataxia–a case series. Artif Organs. 2010;34:1061–5.
doi: 10.1111/j.1525-1594.2010.01140.x
pubmed: 21092049
Raman SV, Phatak K, Hoyle JC, et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur Heart J. 2011;32(5):561–7. https://doi.org/10.1093/eurheartj/ehq443 .
doi: 10.1093/eurheartj/ehq443
pubmed: 21156720
Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263–8.
doi: 10.1161/01.CIR.0000140973.60992.9A
pubmed: 15313958
Lee YR, Briggs MT, Condina MR, et al. Mass spectrometry imaging as a potential tool to investigate human osteoarthritis at the tissue level. Int J Mol Sci 2020;21:6414.
Kitahara T, Takeishi Y, Arimoto T, et al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J. 2007;71:929–35.
doi: 10.1253/circj.71.929
pubmed: 17526992
Cittadini A, Marra AM, Arcopinto M, et al. Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. JACC Heart Fail. 2013;1:325–30.
doi: 10.1016/j.jchf.2013.04.003
pubmed: 24621936
Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
doi: 10.1016/j.echo.2005.10.005
pubmed: 16376782
Bürk K, Schulz SR, Schulz JB. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem. 2013;126(Suppl 1):118–24.
doi: 10.1111/jnc.12318
pubmed: 23859347
Rauchenzauner M, Schmid A, Heinz-Erian P, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92:443–9.
doi: 10.1210/jc.2006-1706
pubmed: 17105843
Ho CY, López B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–63.
doi: 10.1056/NEJMoa1002659
pubmed: 20818890
pmcid: 3049917
Mehta N, Chacko P, Jin J, et al. Serum versus imaging biomarkers in Friedreich ataxia to indicate left ventricular remodeling and outcomes. Tex Heart Inst J. 2016;43:305–10.
doi: 10.14503/THIJ-14-4198
pubmed: 27547137
pmcid: 4979385
Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail. 2018;11:e005266.
doi: 10.1161/CIRCHEARTFAILURE.118.005266
pubmed: 30562095
pmcid: 6352308